Medpace (NASDAQ:MEDP) Releases FY 2025 Earnings Guidance

Medpace (NASDAQ:MEDP) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 11.930-12.690 for the period, compared to the consensus estimate of 12.940. The company issued revenue guidance of $2.1 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

Wall Street Analysts Forecast Growth

MEDP has been the topic of several recent analyst reports. Robert W. Baird lifted their price target on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Baird R W downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Finally, TD Cowen cut their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $381.44.

Medpace Stock Down 7.5 %

MEDP opened at $327.86 on Wednesday. Medpace has a twelve month low of $302.01 and a twelve month high of $459.77. The firm has a 50 day moving average price of $344.13 and a 200-day moving average price of $349.34. The stock has a market capitalization of $10.19 billion, a price-to-earnings ratio of 28.71, a PEG ratio of 1.85 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. As a group, analysts expect that Medpace will post 11.93 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.